CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 30 enrolled
Drug / intervention
Nasal Guidecombination
Likely dose
Nasal Guide 0.03 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05918406
NCT05918406Phase 4Completed
CompareCT.gov

A Phase 4, Single Center, Open Label Study Evaluating the Safety of the Nasal Guide Utilized During Administration With Tyrvaya

Oyster Point Pharma, Inc.·interventional·Posted Jun 26, 2023·Updated May 6, 2025

In Brief

A Phase 4 clinical trial evaluating Nasal Guide for Dry Eye and Keratoconjunctivitis Sicca. Completed, enrolled 30 participants across 2 sites.

Detailed Summary

The objective of this study is to determine the safety of the nasal guide when utilized to aid in the administration of Tyrvaya (varenicline solution 0.03mg) Nasal Spray

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye, Keratoconjunctivitis Sicca
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
202420252026
First PostedJun 26, 2023
Enrollment StartJun 14, 2023
Primary CompletionAug 18, 2023
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 3.0 years ago

Interventions

Nasal Guidecombination

Use of Nasal Guide with administration of Tyrvaya (varenicline solution 0.03 mg) BID